Phase I Study of Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2018
At a glance
- Drugs Ibrutinib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 20 Aug 2018 Planned End Date changed from 1 Dec 2020 to 1 Apr 2019.
- 20 Aug 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Apr 2019.
- 20 Aug 2018 Status changed from not yet recruiting to recruiting.